Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novavax (NVAX)
:NVAX
Holding NVAX?
Track your performance easily
NVAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.53 - $23.86
Previous CloseN/A
Volume4.15M
Average Volume (3M)4.25M
Market Cap
$1.36B
Enterprise Value$1.33B
Total Cash (Recent Filing)$235.48M
Total Debt (Recent Filing)$316.34M
Price to Earnings (P/E)―
Beta2.21
Next Earnings
Mar 04, 2025EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.26
Shares Outstanding160,185,000
10 Day Avg. Volume5,894,739
30 Day Avg. Volume4,245,672
Standard Deviation0.51
R-Squared0.04
Alpha0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.62
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue2.14
Enterprise Value/Gross Profit6.28
Enterprise Value/Ebitda-23.12
Forecast
1Y Price Target
$14.20Price Target Upside66.47% Upside
Rating ConsensusHold
Number of Analyst Covering5
Novavax News
PremiumCompany Announcements
Novavax Shares Strategic Updates at Healthcare Conference
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe sale of the Czech Republic manufacturing site to Novo Nordisk provides Novavax with $200M in non-dilutive capital, reinforcing its commitment to an R&D-centric strategy.
Market PotentialNovavax COVID-19 vaccine is widely available in major retailers, capturing over 90% of the season's distribution, making it the only non-mRNA option.
Strategic PartnershipsThere is a high likelihood of securing a large global biopharma partner to pursue a larger-scale vaccine efficacy trial and commercialization, supporting Novavax's growth prospects.
Bears Say
Financial PerformanceCurrent share levels are believed to overvalue the discounted forecasts of associated royalty revenue streams.
Market Share And Demand ConcernsThere is little opportunity for a surge in Nuvaxovid market share during the fall/winter vaccine season.
Regulatory ChallengesThe U.S. FDA is placing a clinical hold on the company's IND application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates.
---
Ownership Overview
0.26% Insiders
12.25% Mutual Funds
<0.01% Other Institutional Investors
69.74% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $3.53 and its highest was $23.86 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $1.36B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Mar 04, 2025 which is in 45 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Nov 12, 2024. The company reported -$0.76 earnings per share for the quarter, beating the consensus estimate of -$0.791 by $0.031.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.66.
How many shares outstanding does Novavax have?
Novavax has 160,185,000 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -$0.76 in its last earnings report, beating expectations of -$0.791. Following the earnings report the stock price went down -6.104%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in NVAX
---
Novavax Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$14.20 (66.47% Upside)
$14.20 (66.47% Upside)
Blogger Sentiment
Bullish
NVAX Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 535.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $119.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
96.54%
12-Months-Change
Fundamentals
Return on Equity
54.11%
Trailing 12-Months
Asset Growth
3.34%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
---
NVAX Company Deck
---
NVAX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments and challenges. The highlights included strategic partnerships and progress in clinical programs, while the lowlights focused on reduced financial guidance and market challenges. The overall sentiment is balanced with both promising opportunities and significant hurdles.Read More>---
NVAX Stock 12 Month Forecast
Average Price Target
$14.20
▲(66.47% Upside)
Technical Analysis
Inovio Pharmaceuticals
―
BioNTech SE
―
Moderna
―
NovoCure
―
SAGE Therapeutics
―
Vir Biotechnology
―
Best Analysts Covering NVAX
1 Year
1 Year Success Rate
20/36 ratings generated profit
1 Year Average Return
+155.67%
reiterated a buy rating last month
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +155.67% per trade.
---